GlassScriptPhysician profile
Quang T Le
NPI 1811947435
$27,275.27
in general payments reported to CMS, 2019-2025
43 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,584 · 2020: $1,421 · 2021: $1,481 · 2022: $2,297 · 2023: $2,994 · 2024: $4,536 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $5,715 · Travel and Lodging: $979 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,397.73 |
| Consulting Fee | $5,715.00 |
| Travel and Lodging | $979.33 |
| Education | $399.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,518.31 | 2022-2025 | Sotyktu |
| Abbvie INC. | $3,498.22 | 2019-2025 | |
| Janssen Biotech, INC. | $1,746.69 | 2019-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $1,686.23 | 2019-2025 | |
| Pfizer INC. | $1,363.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,192.72 | 2019-2025 | |
| Incyte Corporation | $1,163.84 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $1,058.59 | 2019-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $802.83 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $759.22 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $753.60 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $661.87 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $646.96 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Ucb, INC. | $610.24 | 2020-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $544.92 | 2023-2025 | Zoryve |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quang Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.